Actively Recruiting
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Led by AstraZeneca · Updated on 2026-05-11
120
Participants Needed
76
Research Sites
169 weeks
Total Duration
On this page
Sponsors
A
AstraZeneca
Lead Sponsor
P
Parexel
Collaborating Sponsor
AI-Summary
What this Trial Is About
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
CONDITIONS
Official Title
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histopathologically confirmed colorectal adenocarcinoma.
- Provision of FFPE tumor sample collected per standard of care.
- Presence of measurable disease by RECIST 1.1 criteria.
- ECOG performance status of 0 or 1.
- Life expectancy of at least 12 weeks at screening.
- No radiological evidence of liver metastasis.
- No prior systemic therapy for metastatic colorectal cancer except neoadjuvant/adjuvant chemotherapy completed more than 6 months before diagnosis of recurrent or metastatic disease.
- Known mismatch-repair-proficient (pMMR) or microsatellite stable (MSS) metastatic colorectal cancer.
- Adequate organ and bone marrow function.
- Body weight over 35 kg at screening and randomization.
- Use of contraception consistent with local regulations for clinical study participants.
You will not qualify if you...
- Presence of central nervous system metastases or spinal cord compression.
- History of severe allergy to any monoclonal antibody or study intervention.
- Any unresolved toxicity of Grade 2 or higher from previous anticancer therapy.
- History of another primary malignancy.
- Potentially resectable disease planned for radical surgery.
- Active or prior autoimmune, inflammatory, or cardiac disorders.
- Prior history of hypertensive crisis, hypertensive encephalopathy, or bleeding risks.
- History of deep venous thrombosis, pulmonary embolism, arterial thrombosis, transient ischemic attack, or stroke.
- History of abdominal or tracheoesophageal fistula, gastrointestinal perforation, or intraabdominal abscess within 6 months before randomization.
- Prior exposure to immune-mediated therapy.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 76 locations
1
Research Site
Scottsdale, Arizona, United States, 85259
Actively Recruiting
2
Research Site
Los Angeles, California, United States, 90089
Actively Recruiting
3
Research Site
Washington D.C., District of Columbia, United States, 20007
Not Yet Recruiting
4
Research Site
Chicago, Illinois, United States, 60637
Not Yet Recruiting
5
Research Site
Baltimore, Maryland, United States, 21224
Actively Recruiting
6
Research Site
Boston, Massachusetts, United States, 02114
Completed
7
Research Site
Rochester, Minnesota, United States, 55905
Actively Recruiting
8
Research Site
Trenton, New Jersey, United States, 08690
Not Yet Recruiting
9
Research Site
Rochester, New York, United States, 14618
Actively Recruiting
10
Research Site
Cleveland, Ohio, United States, 44106
Withdrawn
11
Research Site
Portland, Oregon, United States, 97239
Not Yet Recruiting
12
Research Site
Philadelphia, Pennsylvania, United States, 19104
Withdrawn
13
Research Site
Nashville, Tennessee, United States, 37232
Not Yet Recruiting
14
Research Site
Houston, Texas, United States, 77030
Actively Recruiting
15
Research Site
East Melbourne, Australia, 3002
Actively Recruiting
16
Research Site
Wollongong, Australia, 2500
Actively Recruiting
17
Research Site
Woodville South, Australia, 5011
Actively Recruiting
18
Research Site
Victoria, British Columbia, Canada, V8R 6V5
Actively Recruiting
19
Research Site
Barrie, Ontario, Canada, L4M 6M2
Actively Recruiting
20
Research Site
Toronto, Ontario, Canada, M5G 1X6
Actively Recruiting
21
Research Site
Montreal, Quebec, Canada, H3T 1E2
Actively Recruiting
22
Research Site
Beijing, China, 100142
Not Yet Recruiting
23
Research Site
Chengdu, China, 610041
Suspended
24
Research Site
Harbin, China, 150081
Not Yet Recruiting
25
Research Site
Shanghai, China, 200003
Not Yet Recruiting
26
Research Site
Shanghai, China, 200032
Suspended
27
Research Site
Shanghai, China, 201114
Not Yet Recruiting
28
Research Site
Wuhan, China, 430079
Suspended
29
Research Site
Zhengzhou, China, 450000
Suspended
30
Research Site
Bordeaux, France, 33076
Not Yet Recruiting
31
Research Site
Marseille, France, 13273
Withdrawn
32
Research Site
Montpellier, France, 34090
Not Yet Recruiting
33
Research Site
Montpellier, France, 34298
Not Yet Recruiting
34
Research Site
Poitiers, France, 86021
Actively Recruiting
35
Research Site
Saint-Priez En Jarez, France, 42270
Actively Recruiting
36
Research Site
Villejuif, France, 94805
Actively Recruiting
37
Research Site
Berlin, Germany, 10117
Not Yet Recruiting
38
Research Site
Dresden, Germany, 01307
Actively Recruiting
39
Research Site
Essen, Germany, 45147
Actively Recruiting
40
Research Site
Hamburg, Germany, 22763
Actively Recruiting
41
Research Site
Marburg, Germany, 35043
Actively Recruiting
42
Research Site
Bologna, Italy, 40133
Actively Recruiting
43
Research Site
Castelfranco Veneto, Italy, 31033
Not Yet Recruiting
44
Research Site
Florence, Italy, 50134
Actively Recruiting
45
Research Site
Milan, Italy, 20133
Not Yet Recruiting
46
Research Site
Milan, Italy, 20162
Not Yet Recruiting
47
Research Site
Naples, Italy, 80131
Not Yet Recruiting
48
Research Site
Pavia, Italy, 27100
Not Yet Recruiting
49
Research Site
Pisa, Italy, 56100
Not Yet Recruiting
50
Research Site
Roma, Italy, 00168
Not Yet Recruiting
51
Research Site
Amsterdam, Netherlands, 1066 CX
Actively Recruiting
52
Research Site
Maastricht, Netherlands, 6202 AZ
Actively Recruiting
53
Research Site
Zwolle, Netherlands, 8025 AB
Actively Recruiting
54
Research Site
Seoul, South Korea, 03080
Actively Recruiting
55
Research Site
Seoul, South Korea, 06351
Actively Recruiting
56
Research Site
Seoul, South Korea, 06591
Actively Recruiting
57
Research Site
Seoul, South Korea, 5505
Actively Recruiting
58
Research Site
Yongin-si, South Korea, 16995
Actively Recruiting
59
Research Site
Barcelona, Spain, 08035
Actively Recruiting
60
Research Site
Barcelona, Spain, 8003
Actively Recruiting
61
Research Site
Madrid, Spain, 28007
Not Yet Recruiting
62
Research Site
Madrid, Spain, 28034
Actively Recruiting
63
Research Site
Madrid, Spain, 28041
Actively Recruiting
64
Research Site
Málaga, Spain, 29010
Actively Recruiting
65
Research Site
Pamplona, Spain, 31005
Actively Recruiting
66
Research Site
Santander, Spain, 39008
Actively Recruiting
67
Research Site
Valencia, Spain, 46010
Actively Recruiting
68
Research Site
Kaohsiung City, Taiwan, 80756
Actively Recruiting
69
Research Site
Taipei, Taiwan, 10002
Actively Recruiting
70
Research Site
Taoyuan, Taiwan, 333
Actively Recruiting
71
Research Site
Yung Kang City, Taiwan, 71044
Actively Recruiting
72
Research Site
Cambridge, United Kingdom, CB2 0XY
Actively Recruiting
73
Research Site
London, United Kingdom, NW1 2PG
Actively Recruiting
74
Research Site
London, United Kingdom, W12 0HS
Actively Recruiting
75
Research Site
Manchester, United Kingdom, M20 4GJ
Actively Recruiting
76
Research Site
Metropolitan Borough of Wirral, United Kingdom, CH63 4JY
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here